Core Insights - The core viewpoint of the article is that Weisheng Pharmaceutical's innovative product, Weizhen Gao® (long-acting growth hormone), has received approval from the National Medical Products Administration, marking a significant milestone in the growth hormone market due to its unique technology and clinical advantages [1][2]. Product Core: Building a Differentiated Moat - Weizhen Gao® is the first long-acting growth hormone that maintains the natural structure of the active molecule, overcoming a significant industry technical barrier [2]. - The product utilizes a unique "TransCon" technology platform that allows for the temporary connection of the growth hormone with an inert carrier, enabling a controlled release of the active ingredient [2][3]. - Clinical studies have shown that Weizhen Gao® has superior efficacy compared to daily administration growth hormones, with significant improvements in annualized growth rate (AHV) and height standard deviation score (SDS) [3][4]. Market Strategy: Differentiated Commercial Pathway - The pricing strategy for Weizhen Gao® will reflect its unique attributes, with an expected annual treatment cost significantly higher than other long-acting growth hormones, justified by its clinical and technical advantages [7][8]. - Weisheng Pharmaceutical has adopted a "light asset, heavy cooperation" approach for market expansion, partnering with established companies for distribution and promotion [8][9]. - The company aims to establish a comprehensive "screening-diagnosis-management" process through collaborations with high-end private hospitals [9]. Team Building: High Standards for Execution - The company emphasizes a rigorous recruitment and training process for its commercial team, ensuring a high level of expertise and industry experience [10]. - A strict assessment mechanism is in place to maintain high standards of knowledge and performance among team members [10]. Long-term Outlook: From Single Product to Platform Value - The approval of Weizhen Gao® paves the way for future products under the TransCon technology platform, with significant sales potential anticipated for upcoming products targeting various endocrine disorders [14]. - The company aims to establish itself as a leading player in the endocrine and metabolic field, with a long-term goal of becoming a billion-dollar innovative pharmaceutical enterprise [14].

Core Viewpoint - The approval of Longpei Growth Hormone Injection (Skytrofa) by Weisheng Pharmaceutical marks a significant advancement in the long-acting growth hormone market, being the only product that outperforms daily formulations for treating pediatric growth hormone deficiency (PGHD) [1][5][6]. Product Differentiation - Longpei Growth Hormone utilizes a natural molecular structure identical to the amino acid sequence of human growth hormone, distinguishing it from other recombinant products [1]. - The product's unique pricing strategy focuses on the mid-to-high-end market, leveraging its differentiated advantages and aligning with the needs of families seeking effective treatment options for their children [3][19]. Clinical Efficacy - Clinical trial data indicates that Longpei Growth Hormone achieves an annualized growth rate of 10.66 cm after 52 weeks, significantly higher than the 9.75 cm achieved with traditional daily formulations [5][6]. - It is the only long-acting growth hormone approved by the National Medical Products Administration (NMPA) with a label stating it is superior to daily formulations, providing a strong basis for physician prescriptions and parental choices [6]. Safety and Convenience - Longpei Growth Hormone has demonstrated a safety profile comparable to daily formulations, with a low incidence of adverse events, primarily mild to moderate [7]. - The product requires only weekly injections, reducing the frequency of administration and enhancing the overall patient experience, while also being stable at room temperature for six months [7]. Value-Added Services - Weisheng Pharmaceutical is collaborating with high-end private medical institutions to provide comprehensive after-sales services, tracking patient progress and adjusting treatment plans as necessary [8]. Market Potential - Analysts predict that Longpei Growth Hormone could achieve sales exceeding 1 billion RMB by 2028, supported by successful overseas market performance and a robust domestic channel strategy [11][12]. - The company has established partnerships with key players in the industry to enhance market penetration and distribution efficiency, targeting different customer segments effectively [13][16][17]. Industry Dynamics - The growth hormone market is undergoing a transformation, with the entry of Longpei Growth Hormone filling a gap in the high-end segment and responding to the increasing demand for quality and safety in pediatric treatments [25][28]. - The overall market for growth hormones is expected to reach approximately 20 billion RMB by 2030, with long-acting formulations projected to capture a significant share due to their convenience and efficacy [19][27]. Investment Value - Weisheng Pharmaceutical's transition from a research-focused entity to a commercially viable company is seen as a pivotal moment for its valuation, with the successful launch of Longpei Growth Hormone serving as a catalyst for future growth [21][26]. - The company's diversified pipeline, including other innovative treatments, positions it well for sustained growth and market relevance [26].

Core Insights - The long-acting growth hormone market in China is experiencing rapid growth, with market share increasing from less than 10% in 2018 to over 35% in 2023, driven by demands for efficacy and treatment experience [1][2]. Product Breakthrough - The core product of Weisheng Pharmaceutical, Lonapegsomatropin, has received approval from the National Medical Products Administration, marking it as the first product in China with both long-acting and natural structure advantages, addressing unmet clinical needs [2][3]. - Lonapegsomatropin is the only long-acting growth hormone (LAGH) clinically proven to outperform daily growth hormone formulations, showcasing its Best-in-Class (BIC) attributes [3][4]. Clinical Validation - Weisheng has completed critical Phase III trials for Lonapegsomatropin in treating pediatric growth hormone deficiency (PGHD), demonstrating its efficacy and safety compared to daily injections [4][5]. - Multiple key Phase III trials globally support the product's use in initial treatment, conversion therapy, and long-term medication, providing solid evidence for its market introduction [5]. Commercialization Strategy - The approval of Lonapegsomatropin represents a pivotal moment for Weisheng, which has established a comprehensive commercialization system to facilitate product launch and market penetration [6][7]. - A strategic partnership with Anke Bio will enhance the promotion of Lonapegsomatropin in China, leveraging Anke's extensive experience and market presence in the growth hormone sector [7]. Market Potential - The global market for Lonapegsomatropin has already seen success, with sales in the U.S. projected to grow from €179 million in 2023 to €206 million by 2025, indicating strong market acceptance [8]. - In China, there is a significant supply-demand gap in PGHD treatment, with an estimated 3.4 million patients and a treatment rate of only 5.3%, suggesting substantial growth potential for long-acting growth hormones [8]. Pipeline and Future Growth - Weisheng's pipeline includes promising candidates for other endocrine disorders, reinforcing its long-term growth strategy and market presence [9]. - The commercialization of Lonapegsomatropin is expected to generate continuous cash flow and support the development of future products, marking a new phase of accelerated growth for the company [9]. Market Positioning - The Hong Kong innovative pharmaceutical sector is transitioning from a research-driven valuation to a profit realization phase, with Weisheng positioned as a rare entity with an approved long-acting growth hormone product [10]. - The competitive landscape for long-acting growth hormones in China is becoming clearer, with Lonapegsomatropin expected to steadily increase its market share over the next 3-5 years, positively impacting the company's valuation [10].

Core Insights - The long-acting growth hormone market in China has seen a significant increase, with its market share rising from less than 10% in 2018 to over 35% in 2023, driven by the dual demand for "treatment efficacy certainty" and "treatment experience" [1] - The approval of Weisheng Pharmaceutical's long-acting growth hormone, Lonapegsomatropin, marks a critical milestone for the company, positioning it as a potential "best-in-class" product in the market [2] - The product addresses key issues in pediatric growth hormone deficiency treatment, particularly the challenges of treatment adherence and efficacy stability, with a unique weekly dosing regimen [3][4] Product Breakthrough - Lonapegsomatropin is the first long-acting growth hormone in China that combines a weekly administration schedule with a natural hormone structure, providing a targeted solution to existing treatment challenges [3] - The product has demonstrated superior efficacy compared to daily injection formulations in clinical trials, establishing its best-in-class status [4] - The innovative TransCon prodrug technology allows for a safer and more effective release of growth hormone, reducing the incidence of adverse reactions [4] Commercialization Strategy - Weisheng Pharmaceutical has established a comprehensive commercialization framework to support the product's market entry, including partnerships to enhance distribution and reach [6][7] - The company has signed a strategic cooperation agreement with Anke Bio, leveraging its extensive experience and market presence to accelerate the promotion of Lonapegsomatropin [7] - The product has already achieved commercial validation in global markets, with significant sales growth projected in the coming years [7] Market Potential - There is a substantial unmet need in the pediatric growth hormone deficiency treatment market in China, with an estimated 3.4 million patients and a treatment rate of only 5.3% [8] - The long-acting growth hormone market is expected to capture approximately 80% of the overall growth hormone market by 2030, with Weisheng aiming for a 15%-20% market share [8] - The company’s pipeline includes additional promising products, enhancing its long-term growth prospects and market positioning [8] Industry Context - The Hong Kong innovative pharmaceutical sector is transitioning from a "research-driven valuation" to a "profit realization valuation" phase, with Weisheng's product launch aligning with this trend [10] - The competitive landscape for long-acting growth hormones in China is becoming clearer, with Lonapegsomatropin expected to steadily increase its market share over the next 3-5 years [10] - The successful commercialization of Lonapegsomatropin is anticipated to significantly enhance the company's valuation and performance, reflecting its industrial development capabilities [10]

Core Viewpoint - The approval of Weisheng Pharmaceutical's long-acting growth hormone injection marks a significant advancement in the domestic growth hormone market, addressing compliance issues associated with daily injections for children with growth hormone deficiency [1][2]. Industry Overview - The Chinese growth hormone market has surged from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [1]. - The long-acting growth hormone market is expected to surpass short-acting products within two years and capture 80% of the total market by 2030 [1]. Competitive Landscape - Existing competitors in the long-acting growth hormone space include Changchun High-tech's Jinsai Pharmaceutical, Teva Biopharma, and Novo Nordisk, with Jinsai and Teva's products already included in the national medical insurance directory for 2025 [2]. - Weisheng's long-acting growth hormone is the only one clinically proven to outperform daily formulations, offering both long-lasting effects and maintaining the natural structure of growth hormone molecules [2]. Product Advantages - Weisheng's long-acting growth hormone can be stored at room temperature below 30 degrees Celsius for up to six months, enhancing convenience for patients compared to other products that require refrigeration [2]. - The pricing strategy for Weisheng's product is anticipated to be higher than currently insured long-acting growth hormones, which have seen significant price reductions due to insurance coverage [3]. Commercial Strategy - Weisheng has partnered with Anke Bio to leverage its extensive commercial experience in the growth hormone sector, focusing on coastal provinces while Anke manages other regions [3]. - The company aims to target private clinics, where a significant portion of growth hormone treatments occur, to reach potential patients effectively [4]. Future Developments - There is potential for the introduction of even longer-acting monthly formulations, with ongoing clinical trials for a novel ultra-long-acting growth hormone [4].

Core Insights - Long-acting growth hormone, Longpei, developed by Weisheng Pharmaceutical, has shown strong commercial growth since its approval in Europe and the U.S. [1] - Longpei is the only long-acting growth hormone that continuously releases unmodified human growth hormone in the body between weekly doses, utilizing TransCon technology [1] - The product offers a convenient weekly dosing regimen, reducing injection frequency by 86% compared to daily formulations, and has demonstrated superior efficacy in clinical trials [1] - The approval of Longpei marks it as the third long-acting growth hormone approved in China for treating pediatric growth hormone deficiency (PGHD) [2] Company Insights - Weisheng Pharmaceutical is expected to enhance its commercialization framework based on the substantial progress of its innovative pipeline, positively impacting its growth prospects [1] - The introduction of Longpei fills a technological gap in the domestic market, which is primarily dominated by daily formulations, providing new treatment options for patients [1]

Core Viewpoint - The approval of Lonapegsomatropin (SKYTROFA) by the National Medical Products Administration of China marks a significant advancement in the treatment of pediatric growth hormone deficiency, providing a long-acting alternative to daily injections [1][2]. Group 1: Product Approval and Efficacy - Lonapegsomatropin has received a Biologics License Application (BLA) approval for treating growth hormone deficiency in children aged 3 years and older in China [1]. - The drug has demonstrated superior efficacy in a Phase 3 trial, showing an annualized height velocity of 10.66 cm/year compared to 9.75 cm/year for daily injections, with a statistically significant difference of 0.91 cm/year (P=0.0010) [2]. - The height standard deviation score (SDS) increased by 1.01 in the Lonapegsomatropin group versus 0.83 in the daily injection group, with a p-value of 0.0015, indicating significant improvement from week 13 of treatment [2]. Group 2: Commercialization Strategy - Following the BLA approval, the company has initiated a comprehensive commercialization plan to ensure supply and expand market coverage [3]. - A commercial supply agreement has been established with Ascendis Pharma to secure the availability of Lonapegsomatropin upon market launch [3]. - The company is enhancing its commercialization capabilities through a dedicated team and tailored strategies for market access and physician awareness, alongside strategic partnerships with Shanghai Pharmaceuticals, United Family Healthcare, and Anke Bioengineering for distribution and promotion [3].

Group 1 - The core product of Weisheng Pharmaceutical-B, Longpei Growth Hormone, is expected to be approved soon, having completed its supplementary data task on January 12, 2026 [1] - Longpei Growth Hormone is the first long-acting growth hormone prodrug approved for use in children with Growth Hormone Deficiency (GHD) in the US and Europe, which could significantly enhance patient compliance compared to daily formulations [1][2] - The stock of Weisheng Pharmaceutical-B has risen over 16% this year, outperforming the Hang Seng Index, which has increased by over 4% during the same period [1] Group 2 - Longpei Growth Hormone, introduced by Weisheng Pharmaceutical from Ascendis Pharma, utilizes TransCon technology for long-acting delivery, showing superior efficacy and equivalent safety compared to short-acting growth hormones [2] - The drug has completed critical Phase III trials in China, demonstrating its effectiveness in comparison to short-acting growth hormones [2]

Core Viewpoint - Viesheng Pharmaceutical-B (02561) has seen a significant stock price increase, with a rise of over 9% during trading, currently up 7.13% at HKD 37.24, driven by the anticipated approval of its core product, Lonapegsomatropin, expected on January 12, 2026 [1] Company Summary - Lonapegsomatropin is a long-acting growth hormone prodrug developed by Viesheng Pharmaceutical-B, licensed from Ascendis Pharma, utilizing TransCon technology for the treatment of Growth Hormone Deficiency (GHD) in children [1] - The product is designed for once-weekly subcutaneous injection, releasing unmodified natural growth hormone, and has already received approval in Europe and the United States [1] Industry Summary - The domestic growth hormone market primarily consists of daily formulations, and the introduction of a weekly formulation is expected to significantly enhance patient compliance [1] - The anticipated launch of Lonapegsomatropin is likely to reshape the competitive landscape and address unmet clinical needs in the market [1]

Core Viewpoint - The approval of Yipeisheng (益佩生), a long-acting growth hormone injection by Tebao Biopharma, marks a significant shift in the long-acting growth hormone market, breaking the decade-long monopoly held by Jinsai Pharmaceutical [2][4]. Company Summary - Tebao Biopharma's Yipeisheng is designed for weekly administration, targeting growth hormone deficiency in children aged three and above, enhancing patient compliance and reducing treatment burden [2][3]. - The company reported a revenue of 2.817 billion yuan in 2024, a year-on-year increase of 34.13%, and a net profit of 828 million yuan, up 49% year-on-year [6]. - The company has five existing products, with Paigebin being the main revenue driver, generating 2.447 billion yuan, accounting for over 80% of total revenue [6]. Industry Summary - The long-acting growth hormone market has been dominated by Jinsai Pharmaceutical for over ten years, with its product "Jinsai Zeng" being the first globally approved long-acting growth hormone [3][4]. - The market for growth hormone treatment in China is significant, with approximately 6.4 million children affected by growth hormone deficiency, indicating a substantial unmet medical need [3]. - The entry of Yipeisheng is expected to intensify competition in the long-acting growth hormone sector, potentially leading to expanded indications and increased market share for long-acting products [4].